<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) is the main cause of premature <z:hpo ids='HP_0011420'>death</z:hpo> in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> (CKD) </plain></SENT>
<SENT sid="1" pm="."><plain>The underlying mechanisms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in patients with mild to moderate CKD are different from those with <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>While serum cholesterol is frequently elevated and contributes to <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> in many CKD patients, particularly those with nephrotic <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, it is usually <z:mpath ids='MPATH_458'>normal</z:mpath>, even subnormal, in most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> patients receiving hemodialysis </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> population is primarily driven by <z:mp ids='MP_0003674'>oxidative stress</z:mp>, <z:mp ids='MP_0001845'>inflammation</z:mp>, accumulation of the oxidation-prone intermediate-density <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, chylomicron remnants and small dense <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> particles as well as <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> deficiency and dysfunction, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0004934'>vascular calcification</z:hpo>, and <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Only a minority of hemodialysis patients have <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> which is most likely due to genetic or unrelated factors </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, due to peritoneal losses of proteins which simulate <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo>, peritoneal dialysis patients often exhibit <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Clearly when present, <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> contributes to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in the CKD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> population and justifies cholesterol-lowering therapy </plain></SENT>
<SENT sid="7" pm="."><plain>However, the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> patients and a subpopulation of CKD patients with minimal <z:hpo ids='HP_0000093'>proteinuria</z:hpo> have <z:mpath ids='MPATH_458'>normal</z:mpath> or subnormal serum cholesterol levels and do not benefit from and can be potentially harmed by <z:chebi fb="0" ids="35664">statin</z:chebi> therapy </plain></SENT>
<SENT sid="8" pm="."><plain>In fact the lack of efficacy of <z:chebi fb="0" ids="35664">statins</z:chebi> in hemodialysis patients has been demonstrated in several randomized clinical trials </plain></SENT>
<SENT sid="9" pm="."><plain>This review is intended to provide an overview of the mechanisms responsible for the failure of <z:chebi fb="0" ids="35664">statins</z:chebi> to reduce <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> and mortality in most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> patients and to advocate the adoption of individualized care principles in the management of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> in this population </plain></SENT>
</text></document>